Core Insights - Edwards Lifesciences Corporation reported fourth-quarter 2025 adjusted earnings per share (EPS) of 58 cents, missing the Zacks Consensus Estimate by 5.89% and reflecting a 1.7% year-over-year decline [1] - Full-year adjusted EPS was $2.56, a 5.3% increase from 2024, but also missed the Zacks Consensus Estimate by 1.2% [2] Revenue Performance - Total sales for the fourth quarter reached $1.57 billion, marking a 13.3% year-over-year increase and surpassing the Zacks Consensus Estimate by 1.99% [3] - Full-year revenues for 2025 amounted to $6.07 billion, up 11.5% year over year, also beating the Zacks Consensus Estimate by 0.7% [3] Segment Sales Analysis - Transcatheter Aortic Valve Replacement (TAVR) sales were $1.16 billion, up 12% year over year, driven by increased focus on SAPIEN therapy [4] - Transcatheter Mitral and Tricuspid Therapies (TMTT) sales reached $155.7 million, a significant 48.3% increase from the prior year, exceeding projections [5] - Surgical Structural Heart sales totaled $253.6 million, reflecting a 3.8% year-over-year growth despite some inventory adjustments [6] Margin and Cost Analysis - Gross profit was $1.22 billion, a 12.2% increase year over year, but gross margin contracted by 77 basis points to 78.2% due to a 17.4% rise in cost of sales [7] - Selling, General and Administrative (SG&A) expenses rose 22.6% year over year to $602.9 million, while R&D expenditures decreased by 1.3% to $267.7 million [7] Future Guidance - For 2026, the company projects sales growth of 8% to 10%, with adjusted EPS expected in the range of $2.90 to $3.05 [11] - The first quarter of 2026 is projected to have total sales between $1.55 billion and $1.63 billion, with adjusted EPS in the range of 70 to 76 cents [12] Overall Performance Summary - Despite an earnings miss, Edwards Lifesciences experienced revenue growth and expressed confidence in its 2026 outlook, supported by strong quarterly performance and ongoing adoption of its therapies [13]

Financial Data and Key Metrics Changes - The company reported total sales of $1.57 billion for Q4 2025, reflecting an 11.6% year-over-year growth, and a full-year growth of 10.7% [5][22] - Adjusted earnings per share (EPS) for Q4 was $0.58, while GAAP EPS was $0.11, impacted by one-time charges related to the JenaValve acquisition and litigation expenses [22][24] - The adjusted gross profit margin for Q4 was 78.3%, slightly down from 79.0% in the previous year, attributed to increased manufacturing expenses [23][24] Business Line Data and Key Metrics Changes - TAVR global sales reached $1.16 billion in Q4, increasing by 10.6% year-over-year, with procedural growth in the high single digits [10][11] - TMTT sales grew over 40% to $156 million in Q4, with full-year sales exceeding $1 billion [16] - Surgical product group sales for Q4 were $254 million, a 2% increase year-over-year, with full-year sales surpassing $1 billion [18] Market Data and Key Metrics Changes - The U.S. and international markets showed comparable TAVR procedural growth, with stable average pricing and competitive positioning globally [11][15] - In Europe, TAVR results reflected healthy underlying procedural growth, supported by updated clinical guidelines [14][15] Company Strategy and Development Direction - The company focuses solely on Structural Heart, aiming to solve complex patient needs and innovate within the market [5][9] - Plans to pioneer new therapies and expand indications over the next three years, with a long-term sales growth expectation of 10% annually [10][29] - The company is investing in patient access initiatives and partnerships, such as with the American Heart Association, to enhance treatment awareness [14][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting 2026 sales growth guidance of 8%-10% and EPS guidance of $2.90-$3.05, citing strong Q4 performance as a foundation [22][27] - The company anticipates a potential tailwind from an updated national coverage determination for TAVR later in the year [8][50] - Management highlighted the importance of timely and equitable access to care for patients, particularly in light of new clinical guidelines [12][76] Other Important Information - The company maintains a strong balance sheet with approximately $3 billion in cash and cash equivalents as of December 31 [25] - The company has about $2 billion remaining under its share repurchase authorization, with plans to continue repurchasing shares opportunistically [26][70] Q&A Session Summary Question: Insights on TAVR growth and market share - Management noted that TAVR grew 10.6% year-over-year, driven by compelling clinical evidence and a renewed focus on proactive treatment [34][35] Question: Increased spending on market access initiatives - The company increased SG&A spending by $112 million year-over-year to support strategic investments in patient access and education [39][40] Question: TAVR NCD and its potential impact - Management indicated that the reopening of the TAVR NCD process is crucial for improving patient access, with a draft expected around June [50][51] Question: LAA market opportunity and differentiation - The company sees significant unmet needs in the LAA market and plans to introduce differentiated technology to address these needs [52][56] Question: Comments on guideline changes in Europe - Management highlighted the shift in European guidelines towards proactive disease management, which is expected to drive procedural growth [76][77]